BOTOX

BOTOX is the trademarked brand name for onabotulinumtoxinA, a purified botulinum toxin type A product used by qualified healthcare professionals. It is one of the best-known names in medical aesthetics, where BOTOX Cosmetic is injected to temporarily reduce the appearance of moderate-to-severe facial lines. The broader BOTOX product is also used in therapeutic medicine for conditions involving excessive or involuntary muscle activity. The product’s medical origins predate its popular association with cosmetic treatment. Botulinum toxin was developed and clinically evaluated as a neuromuscular treatment, and the product became associated with Allergan after the company acquired the business connected with the toxin product. The brand’s cosmetic significance grew substantially after U.S. regulatory approval for glabellar lines in 2002. That approval helped establish injectable wrinkle treatment as a mainstream category and gave the BOTOX name unusually strong recognition beyond the medical profession. BOTOX is not a single-use consumer cosmetic in the ordinary retail sense. It is a prescription medicine administered by licensed and appropriately trained practitioners. Dosage, injection sites, patient selection, contraindications, and expected duration vary by indication and jurisdiction. Cosmetic treatment is commonly described as temporary, with effects requiring periodic maintenance, while therapeutic uses involve condition-specific clinical assessment and dosing. The brand has historically covered both aesthetic and therapeutic applications. Depending on local approvals, therapeutic uses include chronic migraine prevention, upper-limb spasticity, cervical dystonia, blepharospasm, strabismus, overactive bladder, neurogenic detrusor overactivity, and severe primary axillary hyperhidrosis. Regulatory indications are not identical in every country, so a general description of the brand should not be treated as a universal list of approved uses. Corporate ownership changed when AbbVie completed its acquisition of Allergan in 2020. AbbVie retained the BOTOX franchise and separated much of the aesthetics portfolio into an Allergan Aesthetics business, while therapeutic BOTOX activities were integrated into AbbVie’s pharmaceutical organization. This structure reflects the brand’s dual identity: a high-profile aesthetic treatment and an established prescription medicine with a substantial therapeutic portfolio. BOTOX competes with other botulinum toxin products and with non-toxin aesthetic procedures. Competition has included products such as Dysport, Xeomin, Jeuveau, and other locally approved formulations. Differences in formulation, units, labeling, clinical evidence, pricing, distribution, and practitioner familiarity are important because botulinum toxin units are product-specific and should not be assumed to be interchangeable. The BOTOX name is also widely used colloquially to describe botulinum toxin injections generally, although that usage can blur the distinction between the BOTOX trademark and competing products. Public marketing is subject to prescription-drug, healthcare-advertising, professional-conduct, and privacy rules. In some jurisdictions, including the United Kingdom, direct-to-public advertising of prescription-only botulinum toxin treatments is restricted or prohibited. Brand communications therefore commonly emphasize practitioner education, patient information, approved indications, safety, and treatment expectations rather than unrestricted consumer promotion.

BOTOX originated as a medical botulinum toxin type A product rather than as a cosmetic brand. Botulinum toxin temporarily blocks nerve signals to muscles, making it useful in carefully selected conditions involving abnormal or excessive muscle contraction. The product became associated with Allergan after the company acquired the business connected with the toxin medicine and developed it across ophthalmology, neurology, rehabilitation, urology, dermatology, and aesthetic medicine. The brand’s public profile changed when clinicians observed that treatment of facial muscles could soften lines between the eyebrows and other expression-related wrinkles. Allergan developed the aesthetic opportunity while retaining the product’s therapeutic identity. In 2002, the U.S. Food and Drug Administration approved BOTOX Cosmetic for temporary improvement of glabellar lines, commonly described as the vertical lines between the eyebrows. This approval established a formal cosmetic indication and helped transform injectable wrinkle treatment from a specialist procedure into a widely recognized medical-aesthetic category. During the 2000s and 2010s, BOTOX expanded its cultural and commercial reach. Practitioners used the product in additional approved therapeutic settings, while the BOTOX Cosmetic name became closely associated with minimally invasive facial rejuvenation. The brand benefited from repeat treatment patterns, practitioner familiarity, clinical experience, and strong consumer recognition. At the same time, the popularity of the trademark led many people to use “Botox” as a generic term for botulinum toxin injections, even though competing products are separate medicines with their own labels and unit systems. The therapeutic portfolio developed in parallel with the cosmetic business. Depending on regulatory jurisdiction and indication, BOTOX has been used for chronic migraine prevention, focal spasticity, dystonias, certain eye-muscle disorders, overactive bladder, and severe underarm sweating, among other conditions. These uses require medical evaluation and are not interchangeable with cosmetic treatment. The breadth of the portfolio helped make BOTOX both an aesthetics franchise and a pharmaceutical product with specialist clinical applications. Corporate changes shaped the brand’s later organization. Allergan became a major medical-aesthetics and specialty-pharmaceutical company, with BOTOX as one of its most important assets. In 2019, AbbVie agreed to acquire Allergan in a transaction valued at approximately $63 billion; the transaction closed in 2020 after regulatory review. AbbVie used a dedicated Allergan Aesthetics structure for BOTOX Cosmetic and related aesthetic brands, while therapeutic BOTOX was incorporated into AbbVie’s broader pharmaceutical operations. This arrangement preserved the brand’s aesthetic identity while recognizing its medical and prescription-drug role. BOTOX now operates in a competitive market that includes other botulinum toxin formulations, dermal fillers, energy-based devices, surgery, and skincare products. Its continued positioning depends on regulatory compliance, clinical evidence, practitioner training, product authenticity, and responsible communication. Because it is prescription-only in many markets, public-facing promotion is constrained. In the United Kingdom, for example, professional advertising guidance restricts direct advertising of prescription-only medicines such as botulinum toxin to the public. Clinics must also address informed consent, appropriate qualification of injectors, truthful claims, and patient-image permissions. The brand remains active internationally, but approved indications, labeling, availability, and advertising rules vary by country. BOTOX should therefore be understood as a global prescription medicine and aesthetic brand rather than as an unrestricted consumer cosmetic product.

1. 2022BOTOX Cosmetic reaches twentieth U.S. approval anniversary

   Allergan Aesthetics commemorated two decades since the first U.S. FDA approval of BOTOX Cosmetic.

   Source
2. 2020AbbVie completes Allergan acquisition

   The acquisition closed and BOTOX became part of AbbVie, with aesthetic and therapeutic operations organized differently within the combined company.

   Source
3. 2019AbbVie announces Allergan acquisition

   AbbVie announced an approximately $63 billion acquisition of Allergan, whose portfolio included BOTOX.

   Source
4. 2018Competing toxin advances toward market entry

   Evolus advanced DWP-450 through late-stage development and regulatory filings as a competitor to BOTOX.

   Source
5. 2002U.S. cosmetic approval

   BOTOX Cosmetic received its first U.S. FDA approval for temporary improvement of glabellar lines.

   Source

A clinically established, premium-recognition botulinum toxin brand spanning medical aesthetics and prescription therapeutics.

• BOTOX CosmeticAesthetic injectable2002

  BOTOX Cosmetic is the aesthetic presentation of onabotulinumtoxinA. Administered by qualified practitioners, it temporarily reduces the appearance of selected dynamic facial lines by relaxing targeted muscles. Its best-known approved use is treatment of glabellar lines, with additional labeling varying by jurisdiction. It is a prescription treatment, not an over-the-counter beauty product, and outcomes depend on anatomy, technique, dose, and patient expectations.

• Therapeutic BOTOXPrescription therapeutic medicine

  Therapeutic BOTOX refers to onabotulinumtoxinA used for approved medical indications. Depending on market authorization, these include chronic migraine prevention, muscle spasticity, dystonias, certain ophthalmic disorders, overactive bladder conditions, and severe underarm sweating. Each indication has its own clinical criteria, dosing approach, safety considerations, and regulatory labeling.

• 2022BOTOX Cosmetic twentieth-anniversary communications

  United States

  Allergan Aesthetics used anniversary communications to highlight twenty years since the first U.S. FDA approval of BOTOX Cosmetic.

  Outcome. The anniversary reinforced the product’s longevity and category leadership in medical aesthetics.

  Source

• 2020Transfer of BOTOX ownership to AbbVieM&A

  AbbVie’s acquisition of Allergan brought the BOTOX franchise into AbbVie’s portfolio.

  What changed. AbbVie completed the transaction and organized aesthetic products in a separate Allergan Aesthetics unit while integrating therapeutic BOTOX into its pharmaceutical business.

  Aftermath. BOTOX continued under AbbVie ownership with separate commercial treatment of its aesthetic and therapeutic activities.

  Transaction value. Approximately $63 billion (Announced 2019; completed 2020)

  • Evolus — Evolus pursued development and financing for DWP-450, a competing botulinum toxin product.
  Source

• 2022BOTOX Cosmetic marks 20 years since first U.S. FDA approval

  Allergan Aesthetics announced the twentieth anniversary of the U.S. approval of BOTOX Cosmetic for aesthetic treatment.

  OtherProduct generation
  Source
• 2022FDA approved Botox Cosmetic for forehead lines

  The U.S. FDA approved Botox Cosmetic for the temporary improvement of moderate-to-severe forehead lines in adults, adding to its established cosmetic indications for glabellar and lateral canthal lines.

  Product launch
  Source
• 2020AbbVie completes acquisition of Allergan

  AbbVie completed its acquisition of Allergan, bringing the BOTOX brand into AbbVie’s portfolio and creating a dedicated aesthetics business structure alongside integration of therapeutic products.

  M&A
  Source
• 2020AbbVie plans a separate unit for Allergan’s aesthetics portfolio

  AbbVie announced that BOTOX Cosmetic and other aesthetics brands would be marketed through a separate Allergan Aesthetics subsidiary, while therapeutic BOTOX would sit within AbbVie’s pharmaceutical organization.

  M&A
  Source
• 2020AbbVie completed its acquisition of Allergan

  AbbVie completed the acquisition of Allergan, bringing the Botox brand into AbbVie's portfolio of aesthetics and therapeutic products.

  M&A
  Source
• 2018Evolus prepares to challenge BOTOX with a competing toxin

  Evolus pursued public financing and regulatory filings for DWP-450, a competing botulinum toxin product intended to enter the market dominated by Allergan’s BOTOX.

  Product launchOther
  Source

1. BOTOX Cosmetic marks 20 years since first U.S. FDA approval
2. AbbVie to house Allergan Botox business in separate unit
3. Botox maker Allergan bought by US drug giant for $63bn
4. Evolus plans IPO to bring Botox biosimilar to market
5. AbbVie completes Allergan acquisition
6. FDA approved Botox Cosmetic for forehead lines
7. AbbVie completed its acquisition of Allergan